Brief: Nicox End-Sept Cash And Cash Equivalents Of EUR 25.6 Million

Nicox SA

19/10/2022 06:33

Oct 19 (Reuters) - Nicox SA  NCOX.PA :
    * REG-NICOX PROVIDES THIRD QUARTER 2022 FINANCIAL AND
BUSINESS
HIGHLIGHTS
    * TOPLINE RESULTS OF NCX 470MONT BLANC PHASE 3GLAUCOMA TRIAL
DUE
IN EARLY NOVEMBER 2022
    * Q3 2022 U.S. PRESCRIPTIONS FOR VYZULTA INCREASED BY 37 %
OVER Q3
    * NET REVENUE EUR 0.8 MILLION FOR Q3 2022; CASH OF EUR 25.6
MILLION ON SEPTEMBER 30, 2022
    * AS OF SEPTEMBER 30, 2022, NICOX GROUP HAD CASH AND CASH
EQUIVALENTS OF EUR 25.6 MILLION AS COMPARED WITH EUR 42.0
MILLION AS OF DECEMBER 31, 2021
    * COMPANY ESTIMATES THAT IT IS FINANCED UNTIL OCTOBER 31,
2023,
AND UNTIL NOVEMBER 30, 2023
    * MONT BLANC PHASE 3 CLINICAL TRIAL EVALUATING NCX 470 IN
PATIENTS
WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION: TOPLINE RESULTS
DUE IN EARLY NOVEMBER 2022
    * AS OF SEPTEMBER 30, 2022, NICOX GROUP HAD FINANCIAL DEBT
OF EUR
20.6 MILLION CONSISTING OF EUR 18.6 MILLION IN FORM OF A BOND
FINANCING AGREEMENT

Source text for Eikon:  ID:nGNE8DN0ST 
Further company coverage:  NCOX.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))